The anti-CD19 antibody B43 is used together with anti-CD3, which is present on T cells, in the bispecific T-cell engager (BiTE) blinatumomab that targets CD19-positive B acute lymphoblastic leukemia (ALL) blasts and CLL cells [101,102,103]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.